Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAnesthesiologyPremera Bluecross IV Anesthetics Coverage Update |…
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.586

    Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.586 alerts

    Get alerted when Policy 5.01.586 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines Premera Bluecross's coverage stance on intravenous infusion of anesthetic agents (notably ketamine and lidocaine) when used to treat chronic pain syndromes or psychiatric and substance use disorders, and describes coding and evidence considerations for providers.

    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational designationcoding update
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit appropriate procedure codes on claims and verify member benefits prior to providing IV anesthetic infusion services, which are designated investigational and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    IV ketamine is considered investigational in any setting or in conjunction with any other service, not just when it is either monotherapy or in conjunction with psychotherapy.

    In addition to IV ketamine, any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are also considered investigational.

    HCPCS code J2001 was removed from the policy (termed October 1, 2024).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    InvestigationalCoverage stance for IV anesthetics
    100+Trials listed on ClinicalTrials.gov
    2–4 weeksTypical short-term benefit duration
    N=68Larger RCT size
    >=4Professional organizations referenced

    Coverage Criteria and Policy Stance

    Investigational / Not covered with criteria

    Intravenous infusion of anesthetics for the following indications is considered investigational:

    Investigational therapies: Intravenous infusion of ketamine for treatment of depression, anxiety, other psychiatric symptoms or disorders, substance use disorders, and/or chronic pain (including ketamine-assisted psychotherapy) is investigational in any setting or in conjunction with any other service. This includes any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered.

    Supported by policy statement; see chunk 3.

    Other IV anesthetics: Intravenous infusion of any other anesthetics (e.g., lidocaine) for the treatment of chronic pain, including but not limited to chronic neuropathic pain, chronic daily headache, and fibromyalgia, is investigational.

    Supported by policy statement; see chunk 3.

    Investigational (Not Covered) — IV ketamine and associated services

    IV ketamine and associated services are considered investigational under the following clarified policy statements:

    Investigational designation: IV ketamine is considered investigational in any setting or in conjunction with any other service. In addition, any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are also considered investigational.

    Clarification effective 07/01/26 expanded previous wording; see history and policy statement (chunks 32 and 3).

    This policy designates intravenous (IV) infusion of anesthetic agents for the treatment of chronic pain syndromes and psychiatric or substance use disorders as investigational. Specifically, IV ketamine for depression, anxiety, other psychiatric symptoms or disorders, substance use disorders, and/or chronic pain is considered investigational, including when provided as ketamine-assisted psychotherapy. The policy also designates IV infusion of other anesthetics (for example, lidocaine) for chronic pain indications (including chronic neuropathic pain, chronic daily headache, and fibromyalgia) as investigational.

    Claims involving these investigational services may be denied because the policy does not support coverage for these uses; see the coding and provider-action sections for billing guidance and documentation expectations.

    This medical policy does not apply to Medicare Advantage. Members and providers should consult the member benefit booklet or contact a customer service representative to determine coverage for a specific medical service or supply under a given benefit plan.

    The available evidence includes systematic reviews, randomized controlled trials, and observational studies for IV anesthetic infusions (ketamine and lidocaine) in chronic pain and various psychiatric disorders. For chronic pain, randomized trials of IV lidocaine have not demonstrated a durable benefit; limited randomized evidence for IV ketamine shows only transient symptom relief (typically 2–4 weeks) in some small trials, and some trials used no active control raising concern for placebo effects. For treatment‑resistant depression and other psychiatric disorders, studies report short‑term improvements but are limited by small sizes, variable controls, and short durability of effect. Across conditions, treatment protocols can be intensive, adverse events are common (e.g., headache, anxiety, dissociation, nausea, dizziness), and long‑term safety and effectiveness of repeat courses remain uncertain. Overall, the evidence is insufficient to determine that IV anesthetic infusions improve net health outcomes for the covered indications.

    The policy clarification expands the investigational designation: IV ketamine in any setting or when given in conjunction with any other service is investigational. In addition, the policy explicitly includes as investigational any associated office visits, clinic visits, psychotherapy sessions, evaluation and management encounters, or any other sessions during which IV ketamine is administered. These associated visits or sessions are not supported for coverage when they occur in the context of IV ketamine administration.

    Procedure and Supply Codes

    Procedure and supply codes referencedCPT | HCPCS
    0820TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour.
    0821TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure).
    0822TContinuous in-person monitoring and intervention (e.g., psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.
    96366Each additional hour (list separately in addition to code for primary procedure).
    96374Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug.
    J3490Unclassified drugs
    CPT codes (historic additions)CPT
    0820TNew CPT code added previously (listed in history as added Feb 2024)
    0821TNew CPT code added previously (listed in history as added Feb 2024)
    0822TNew CPT code added previously (listed in history as added Feb 2024)
    HCPCS removedHCPCSNot Covered
    J2001Termed/removed from policy effective October 1, 2024

    Provider Guidance and Billing Actions

    Billing Rule

    Billing: submit specific infusion and monitoring codes; investigational services may not be covered

    Submit the appropriate procedure and drug codes on claims for any IV anesthetic infusion and related monitoring/psychotherapy services; the policy lists CPT codes 0820T, 0821T, 0822T, 96365, 96366, 96367, 96374 and HCPCS J3490 as relevant. Note that services described in the policy are designated investigational and may not meet coverage criteria.

    • Use CPT 0820T, 0821T, 0822T for continuous in-person monitoring/intervention during psychedelic medication therapy (each hour).
    • Use CPT 96365 (initial IV infusion up to 1 hour) and 96366 (each additional hour) or 96374 (IV push) as appropriate.
    • Report HCPCS J3490 for unclassified drugs when applicable.
    • Services are investigational per policy and may be denied despite coding.

    Background and Rationale

    Intravenous subanesthetic infusions of agents such as ketamine or lidocaine have been investigated primarily as short courses—ranging from single infusions to series over days—with variable protocols (bolus followed by infusion, treatment durations from 1–6 hours up to multiple days). Studies have evaluated these approaches for chronic neuropathic pain, chronic daily headache, fibromyalgia, and treatment‑resistant psychiatric disorders (e.g., depression, OCD, PTSD). The literature shows some short‑term symptom improvement in select small trials but limited durability of benefit, potential for significant adverse events, and methodological limitations (small sample sizes, lack of active controls, and possible unblinding), which underpin the policy’s investigational designation.

    Definitions

    inv-19: Chronic daily headache — definition and criteria
    DefinitionChronic daily headache: a headache disorder that occurs 15 or more days a month for at least three months; includes chronic migraine, new daily persistent headache, hemicranias continua, and chronic tension-type headache.
    Typical diagnostic threshold≥15 days per month for ≥3 months.
    Included subtypesChronic migraine; new daily persistent headache; hemicranias continua; chronic tension-type headache.
    Clinical contextListed as an indication evaluated in the policy for IV anesthetic infusions (e.g., lidocaine, ketamine) for chronic pain conditions.
    inv-20: Neuropathic pain — definition and typical features
    DefinitionNeuropathic pain: pain often disproportionate to the extent of the primary triggering injury that may consist of thermal or mechanical allodynia, dysesthesia, and/or hyperalgesia.
    Policy Summary
    PayerPremera Bluecross
    PolicyIntravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
    Policy CodePolicy 5.01.586
    Change TypeClarified investigational designationcoding update
    Effective DateJul 1, 2026
    Last ReviewJun 9, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit appropriate procedure codes on claims and verify member benefits prior to providing IV anesthetic infusion services, which are designated investigational and may be denied.
    SourceLink
    On This Page
    Coverage Criteria and Policy StanceProcedure and Supply CodesProvider Guidance and Billing ActionsBackground and RationaleDefinitions
    Prior Authorization

    Recommend benefit verification / prior authorization check

    Verify member benefits and consider prior authorization/benefit check before scheduling IV anesthetic infusions because coverage is subject to member benefit limits and verification is recommended.

    • Consult the member benefit booklet or contact a member service representative to determine whether the service is covered under the specific plan.
    Documentation Required

    Document alternative/conventional treatments tried or considered before investigational IV anesthetic use

    Document that conventional/standard therapies were considered or tried when relevant — the policy references alternative treatments (e.g., neuropathic pain medications such as pregabalin, non‑narcotic pain relievers, low‑dose antidepressants) as typical management for conditions like fibromyalgia and neuropathic pain.

    • For fibromyalgia, note trials of neuropathic pain medications (e.g., pregabalin), non‑narcotic analgesics, or low‑dose antidepressants.
    • For neuropathic pain, document prior consideration of standard neuropathic pain treatments and that IV anesthetic infusion is investigational for these indications.
    Step Therapy

    No step therapy requirements described

    No step therapy (mandatory prior trial of specific therapies) requirements are specified in the policy; the document discusses standard therapies but does not impose step therapy rules for IV anesthetic infusions.

    • The policy describes conventional treatments (e.g., neuropathic agents) but does not define step therapy protocols to be followed prior to IV anesthetic infusion.
    Documentation Required

    Documentation: record that an IV anesthetic infusion was performed and detail associated visits

    Ensure medical record documentation clearly indicates that an IV anesthetic infusion was provided and include clinical rationale — however, note the policy designates these services as investigational for the listed indications.

    • Document the agent administered, route (intravenous), dose, duration of infusion, and the clinical indication.
    • Record any associated office/clinic visits, psychotherapy sessions, or evaluation and management encounters that occurred during administration.
    Note

    Benefit verification required — consult member booklet or customer service

    Consult the member benefit booklet or contact customer service to confirm whether IV anesthetic infusion services are covered for the specific member—coverage is subject to plan limits.

    • Member contracts differ; confirmation is required to determine coverage for a specific medical service or supply.
    Denial Risk

    Denial risk: IV ketamine or other IV anesthetic infusion claims may be denied as investigational

    Be aware that claims for intravenous infusion of ketamine (including ketamine‑assisted psychotherapy) or other IV anesthetics (e.g., lidocaine) for the policy’s listed indications are considered investigational and may be denied.

    • Investigational designation applies to treatment of depression, anxiety, other psychiatric disorders, substance use disorders, chronic pain (including neuropathic pain, chronic daily headache, fibromyalgia).
    • Include clear documentation if submitting for payment, but expect potential denial due to investigational status.
    Denial Risk

    Investigational designation of IV ketamine and associated visits triggers denial risk

    Note that the policy explicitly designates IV ketamine in any setting and any associated visits or therapy sessions during which it is administered as investigational; these designations trigger noncoverage/denial for those services.

    • The clarified policy states IV ketamine is investigational in any setting or in conjunction with any other service.
    • Any office/clinic visits, psychotherapy sessions, evaluation and management sessions, or other sessions during which IV ketamine is administered are also considered investigational.
    Typical featuresAllodynia (pain from normally nonpainful stimuli), dysesthesia (constant unpleasant or electrical pain sensation), and hyperalgesia (exaggerated response to painful stimuli).
    Duration considerationSymptoms may persist ≥6 months beyond expected recovery after an illness or injury.
    Pathophysiology noteAttributed to peripheral afferent sensitization, neurogenic inflammation, sympathetic afferent coupling, and central sensitization affecting somatosensory, motor, and autonomic circuits.
    inv-21: Off-label use — definition and note that IV lidocaine and IV ketamine for chronic pain/psychiatric disorders are off-label
    DefinitionOff-label use: use of an FDA-approved drug for an indication not included in the approved labeling.
    IV lidocaine statusIV lidocaine is FDA-approved for arrhythmias and local anesthesia; IV lidocaine for chronic pain or psychiatric disorders is off-label.
    IV ketamine statusKetamine hydrochloride injection is FDA-approved for induction and supplementation of anesthesia; IV ketamine for chronic pain or psychiatric disorders is off-label.
    Policy implicationThe policy treats IV lidocaine and IV ketamine for chronic pain and psychiatric disorders as off-label uses when considering evidence and coverage stance.